Welcome to LookChem.com Sign In|Join Free

CAS

  • or

114798-26-4 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 114798-26-4 Structure
  • Basic information

    1. Product Name: Losartan
    2. Synonyms: 2-n-butyl-4-chloro-5-hydroxymethyl-1-[[2-(1H-tetrazol-5-yl)-biphenyl-4-yl]methyl]imidazole;DUP 89;1H-imidazole-5-methanol, 2-butyl-4-chloro-1-[[2-(2H-tetrazol-5-yl)[1,1-biphenyl]-4-yl]methyl]-;[2-butyl-5-chloro-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol;2-butyl-4-chloro-1-[p-(o-1H-tetrazol-5ylphenyl)benzyl]imidazole-5-methanol;2-Butyl-4-chloro-1-[[2-(1H-tetrazol-5-yl)[1,1-biphenyl]-4-yl]methyl-1H-imidazole-5-methanol;Losartan Base;
    3. CAS NO:114798-26-4
    4. Molecular Formula: C22H23ClN6O
    5. Molecular Weight: 422.9106
    6. EINECS: 601-329-8
    7. Product Categories: Isotopically Labeled Pharmaceutical Reference Standard
    8. Mol File: 114798-26-4.mol
    9. Article Data: 55
  • Chemical Properties

    1. Melting Point: 183-184 C
    2. Boiling Point: 682 °C at 760mmHg
    3. Flash Point: 366.3 °C
    4. Appearance: pale yellow solid
    5. Density: 1.35 g/cm3
    6. Vapor Pressure: 8.63E-20mmHg at 25°C
    7. Refractive Index: 1.68
    8. Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
    9. Solubility: DMSO (Slightly), Methanol (Slightly)
    10. PKA: 5-6(at 25℃)
    11. Water Solubility: 4.8mg/L at 20℃
    12. CAS DataBase Reference: Losartan(CAS DataBase Reference)
    13. NIST Chemistry Reference: Losartan(114798-26-4)
    14. EPA Substance Registry System: Losartan(114798-26-4)
  • Safety Data

    1. Hazard Codes: Xi
    2. Statements: 36/37/38
    3. Safety Statements: 26-36
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 114798-26-4(Hazardous Substances Data)

114798-26-4 Usage

Description

Losartan, also known as Cozaar, is a nonpeptide angiotensin II AT1-receptor antagonist. It is an orally active compound with high specificity for the AT1 receptor. Losartan undergoes extensive first-pass metabolism, with the 5-methanol being oxidized to a carboxylic acid, mediated by CYP 2C9 and 3A4 isozymes. The 5-methanol metabolite is approximately 15 times more potent than the parent hydroxyl compound. Losartan is a biphenylyltetrazole with a 1,1'-biphenyl group attached at the 5-position and an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position.

Uses

Used in Pharmaceutical Industry:
Losartan is used as an antihypertensive agent for the treatment of hypertension. It functions as an antagonist of angiotensin type 1, helping to lower blood pressure by blocking the effects of angiotensin II, a potent vasoconstrictor.
Used in Cardiovascular Applications:
Losartan is used as a medication for the treatment of heart failure and to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy. By blocking the AT1 receptor, it helps to prevent the negative effects of angiotensin II on the cardiovascular system, such as vasoconstriction and remodeling of the heart muscle.

Originator

Alsartan, Aristo Pharmaceutical Ltd., India

Manufacturing Process

2-Butyl-4-chloro-1-(2'-(tetrazol-5-yl)biphenyl-4-ylmethyl)-1H-imidazole-5- methanolpotassium was synthesized in 5 stages. 1. Methyl 4'-methylbiphenyl-2-carboxylate (44.2 mmol), 0.5 N KOH in methanol (133 mmol), and water (50 mL) were mixed and refluxed under nitrogen. After 5 hours, the solvent was removed in vacuo and water (200 mL) and ethyl acetate (200 mL) added. The aqueous layer was acidified with concentrated hydrochloric acid to a pH of 3 and the layers were separated. The aqueous phase was extracted with ethyl acetate, the organic layers collected, dried (MgSO4) and the solvent removed in vacuo to yield 8.71 g of a 4'-methylbiphenyl-2-carboxylic acid, melting point 140.0-145.0°C. 2. 4'-Methylbiphenyl-2-carboxylic acid (41 mmol) and thionyl chloride (411 mmol) were mixed and refluxed for 2 hours. The excess thionyl chloride was removed in vacuo and the residue was taken up in toluene. The toluene was removed by rotary evaporation. The crude acid chloride was then added slowly to cold (0°C) concentrated NH4OH (50 mL) so that the temperature was kept below 15°C. After 15 minutes of stirring, water (100 mL) was added and solids precipitated. These were collected, washed with water and dried under high vacuum over P2O5 to yield 7.45 g of a white solid, melting point 126.0-128.5°C. The above product amide (35 mmol) and thionyl chloride (353 mmol) were mixed and refluxed for 3 hours. The thionyl chloride was removed using the same procedure as described above. The residue was washed with a little hexane to yield 6.64 g of 4'-methyl-2-cyanobiphenyl, melting point 44.0- 47.0°C. 3. 4'-Methyl-2-cyanobiphenyl (5.59 g) was brominated using benzoyl peroxide as an initiator. The product was recrystallized from ether to yield 4.7 g of 4'- bromomethyl-2-cyanobiphenyl, melting point 114.5-120.0°C.4. 4'-Bromomethyl-2-cyanobiphenyl (4.6 g) was alkylated onto 2-n-butyl-4- chloro-5-(hydroxymethyl)-imidazole. For separation of the product was used a flash chromatography in 1:1 hexane/ethyl acetate over silica gel. The regioisomeric products yielded 2.53 g of the faster eluting isomer. Recrystallization from acetonitrile yielded 1.57 g of analytically pure 2-n-butyl4-chloro-1-[2'-cyanobiphenyl-4-yl)methyl]-5-(hydroxymethyl)-imidazole, melting point 153.5 -155.5°C. 5. 2-n-Butyl-4-chloro-1-[(2'-cyanobiphenyl-4-yl)-methyl]-5-(hydroxymethyl)- imidazole (10 mmole), sodium azide (10 mmol), and ammonium chloride (30 mmol) were mixed in DMF (150 mL) under N2 at 100°C for 2 days, after which the temperature was raised to 120°C for 6 days. The reaction was cooled and 3 more equivalents each of ammonium chloride and sodium azide were added. The reaction was again heated for 5 days at 120°C. The reaction was cooled, the inorganic salts filtered, and the filtrate solvent removed in vacuo. Water (200 mL) and ethyl acetate (200 mL) were added to the residue and the layers were separated. The aqueous layer was extracted with ethyl acetate, the organic layers were collected, dried (MgSO4) and the solvent removed in vacuo, to yield a dark yellow oil. The product was purified by flash chromatography in 100% ethyl acetate to 100% ethanol over silica gel to yield 5.60 g of a light yellow 2-n-butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1Htetrazol-5-yl)biphenyl-4-yl)methyl]imidazole. Recrystallization from acetonitrile yielded 4.36 g of light yellow crystals which still melted broadly. The crystals were taken up in 100 mL of hot acetonitrile. The solid that did not dissolve was filtered off to yield 1.04 g of product as a light yellow solid, melting point of 2-n-butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4- yl)methyl]imidazole 183.5-184.5°C. 2-n-Butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4- yl)methyl]imidazole may be converted to potassium salt.

Therapeutic Function

Antihypertensive

Flammability and Explosibility

Nonflammable

Check Digit Verification of cas no

The CAS Registry Mumber 114798-26-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,4,7,9 and 8 respectively; the second part has 2 digits, 2 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 114798-26:
(8*1)+(7*1)+(6*4)+(5*7)+(4*9)+(3*8)+(2*2)+(1*6)=144
144 % 10 = 4
So 114798-26-4 is a valid CAS Registry Number.
InChI:InChI=1/C22H23ClN6O/c1-2-3-9-20-24-21(23)19(14-30)29(20)13-15-10-11-17(16-7-5-4-6-8-16)18(12-15)22-25-27-28-26-22/h4-8,10-12,30H,2-3,9,13-14H2,1H3,(H,25,26,27,28)

114798-26-4SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name losartan

1.2 Other means of identification

Product number -
Other names Compound 89

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:114798-26-4 SDS

114798-26-4Synthetic route

2-n-Butyl-4-chloro-1-[(2'-cyanobiphenyl-4-yl)-methyl]-5-(hydroxymethyl)imidazole
114772-55-3

2-n-Butyl-4-chloro-1-[(2'-cyanobiphenyl-4-yl)-methyl]-5-(hydroxymethyl)imidazole

lorsartan
114798-26-4

lorsartan

Conditions
ConditionsYield
With sodium azide In 1-methyl-pyrrolidin-2-one99%
With sodium azide In toluene at 20℃;95%
With sodium azide; zinc trifluoromethanesulfonate In water at 100℃; for 6h; Solvent; Temperature; Time; Green chemistry;91%
methanol
67-56-1

methanol

2-Butyl-4-chloro-1-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol
124751-00-4

2-Butyl-4-chloro-1-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol

A

methoxytriphenylmethane
596-31-6

methoxytriphenylmethane

B

lorsartan
114798-26-4

lorsartan

Conditions
ConditionsYield
for 7h; Heating / reflux;A 90%
B 98%
1-{[2′-(1-benzyl-1H-tetrazol-5-yl)-1,1′-biphenyl-4-yl]methyl}-2-butyl-4-chloro-1H-imidazole-5-carbaldehyde

1-{[2′-(1-benzyl-1H-tetrazol-5-yl)-1,1′-biphenyl-4-yl]methyl}-2-butyl-4-chloro-1H-imidazole-5-carbaldehyde

lorsartan
114798-26-4

lorsartan

Conditions
ConditionsYield
With palladium 10% on activated carbon; hydrogen at 20℃; under 760.051 Torr; for 24h;97%
With palladium on carbon; hydrogen; acetic acid at 20℃; for 12h;94%
Multi-step reaction with 2 steps
1: sodium tetrahydroborate / methanol; toluene / 0.5 h / 25 °C / Inert atmosphere
2: ammonium formate; 5% palladium on barium sulphate / isopropyl alcohol; water / 8 h / 25 - 60 °C
View Scheme
Multi-step reaction with 2 steps
1: sodium tetrahydroborate; methanol / toluene / 0.58 h / 0 - 25 °C
2: 5% palladium on barium sulphate; ammonium formate / water; isopropyl alcohol / 8 h / 60 °C
View Scheme
2-Butyl-4-chloro-1-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol
124751-00-4

2-Butyl-4-chloro-1-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol

A

methoxytriphenylmethane
596-31-6

methoxytriphenylmethane

B

lorsartan
114798-26-4

lorsartan

Conditions
ConditionsYield
Stage #1: 2-Butyl-4-chloro-1-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol With hydroxylamine hydrochloride In methanol; water; acetone at 20℃; for 2h;
Stage #2: With sodium hydroxide In methanol; water; acetone at 20 - 25℃; pH=3.8 - 4.2;
A n/a
B 95%
Stage #1: 2-Butyl-4-chloro-1-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol With hydrogenchloride In methanol; water; acetone at 20℃; for 2h;
Stage #2: With sodium hydroxide In methanol; water; acetone at 20 - 25℃; pH=3.8 - 4.2;
A n/a
B 93%
Stage #1: 2-Butyl-4-chloro-1-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol With sulfuric acid In methanol; water; acetone at 20℃; for 2h;
Stage #2: With sodium hydroxide In methanol; water; acetone at 20 - 25℃; pH=3.8 - 4.2;
A n/a
B 91.3%
ethyl acetate
141-78-6

ethyl acetate

A

C24H25ClN6O2

C24H25ClN6O2

B

methoxytriphenylmethane
596-31-6

methoxytriphenylmethane

C

lorsartan
114798-26-4

lorsartan

Conditions
ConditionsYield
Stage #1: 2-Butyl-4-chloro-1-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol With hydroxylamine hydrochloride In methanol; water; acetone at 20℃; for 2h;
Stage #2: With sodium hydroxide In methanol; water; acetone at 20 - 25℃; pH=3.8 - 4.2;
Stage #3: ethyl acetate at 40℃; for 1h;
A n/a
B n/a
C 95%
2-Butyl-4-chloro-1-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol
124751-00-4

2-Butyl-4-chloro-1-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol

lorsartan
114798-26-4

lorsartan

Conditions
ConditionsYield
Stage #1: 2-Butyl-4-chloro-1-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol; hydroxylamine hydrochloride In methanol at 60℃; for 2.5h; pH=2.95;
Stage #2: With triethylamine In methanol at 0 - 40℃; for 1h; pH=3.6; Product distribution / selectivity;
94.7%
Stage #1: 2-Butyl-4-chloro-1-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol; hydroxyammonium sulfate In isopropyl alcohol at 60 - 65℃; for 4h; pH=2.4;
Stage #2: With triethylamine In isopropyl alcohol at 0 - 5℃; for 2h; pH=3.5; Product distribution / selectivity;
93.8%
With hydrogenchloride; water In tetrahydrofuran at 20℃; for 4h;90%
2-n-butyl-4-chloro-5-hydroxymethyl-1-[[2'-(1H-tetrazole-5-yl)[1,1'-biphenyl]-4-yl]]-1H-imidazole sodium salt

2-n-butyl-4-chloro-5-hydroxymethyl-1-[[2'-(1H-tetrazole-5-yl)[1,1'-biphenyl]-4-yl]]-1H-imidazole sodium salt

lorsartan
114798-26-4

lorsartan

Conditions
ConditionsYield
With sulfuric acid In water; ethyl acetate at 10 - 25℃; for 1h; pH=3.6 - 3.8; Purification / work up;94%
cozaar
124750-99-8

cozaar

lorsartan
114798-26-4

lorsartan

Conditions
ConditionsYield
With sulfuric acid In water; ethyl acetate at 10 - 25℃; for 1h; pH=3.6 - 3.8; Purification / work up;93%
With hydrogenchloride In tetrahydrofuran; water; chlorobenzene86.8%
With hydrogenchloride In tetrahydrofuran; water; chlorobenzene pH=3.5 - 3.6;84%
With hydrogenchloride In tetrahydrofuran; water; chlorobenzene pH=3.5 - 3.6;42.6 g
2-n-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol p-toluenesulfonate

2-n-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol p-toluenesulfonate

lorsartan
114798-26-4

lorsartan

Conditions
ConditionsYield
With potassium hydroxide In water; acetonitrile at 15 - 25℃; pH=3.5 - 3.6;93%
2-n-butyl-4-chloro-1-[(2'-(2-triphenylmethyl-2H-tetrazol-5-yl)-1,1'-biphenyl-4-yl)methyl]-1H-imidazole-5-methanol
133909-99-6

2-n-butyl-4-chloro-1-[(2'-(2-triphenylmethyl-2H-tetrazol-5-yl)-1,1'-biphenyl-4-yl)methyl]-1H-imidazole-5-methanol

lorsartan
114798-26-4

lorsartan

Conditions
ConditionsYield
With hydrogenchloride In tetrahydrofuran at 25℃; for 4h;89%
trityl losartan

trityl losartan

lorsartan
114798-26-4

lorsartan

Conditions
ConditionsYield
With methanol for 4 - 5h; Heating / reflux;88%
(1-{[2′-(1-benzyl-1H-tetrazol-5-yl)-1,1′-biphenyl-4-yl]methyl}-2-butyl-4-chloro-1H-imidazol-5-yl)methanol

(1-{[2′-(1-benzyl-1H-tetrazol-5-yl)-1,1′-biphenyl-4-yl]methyl}-2-butyl-4-chloro-1H-imidazol-5-yl)methanol

lorsartan
114798-26-4

lorsartan

Conditions
ConditionsYield
With 5% palladium on barium sulphate; ammonium formate In water; isopropyl alcohol at 25 - 60℃; for 8h;71%
With 5% palladium on barium sulphate; ammonium formate In water; isopropyl alcohol at 60℃; for 8h; Temperature; Time;70.7%
2-n-Butyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5-carboxaldehyde
114798-36-6

2-n-Butyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5-carboxaldehyde

lorsartan
114798-26-4

lorsartan

Conditions
ConditionsYield
With sodium tetrahydroborate; sodium hydroxide In water at 5 - 20℃; for 4.41667h;65%
With sodium tetrahydroborate; water; sodium hydroxide In acetonitrile at 5 - 25℃; for 4.41667h;29.2%
Stage #1: 2-n-Butyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5-carboxaldehyde With sodium tetrahydroborate In water at 25 - 45℃;
Stage #2: With hydrogenchloride In water at 15 - 20℃; pH=4.0;
C30H33ClN6O2

C30H33ClN6O2

lorsartan
114798-26-4

lorsartan

Conditions
ConditionsYield
Stage #1: C30H33ClN6O2 With trifluoroacetic acid In methoxybenzene at 60℃; for 1.5h;
Stage #2: With potassium hydroxide In water; methoxybenzene
49%
(2-butyl-5-chloro-3-{2'-[2-(1-methyl-1-phenyl-ethyl)-2H-tetrazol-5-yl]-biphenyl-4-ylmethyl}-3H-imidazol-4-yl)-methanol
852357-69-8

(2-butyl-5-chloro-3-{2'-[2-(1-methyl-1-phenyl-ethyl)-2H-tetrazol-5-yl]-biphenyl-4-ylmethyl}-3H-imidazol-4-yl)-methanol

lorsartan
114798-26-4

lorsartan

Conditions
ConditionsYield
Stage #1: (2-butyl-5-chloro-3-{2'-[2-(1-methyl-1-phenyl-ethyl)-2H-tetrazol-5-yl]-biphenyl-4-ylmethyl}-3H-imidazol-4-yl)-methanol With water; hydrogen bromide at 15 - 20℃; for 4h;
Stage #2: With sodium acetate In water Product distribution / selectivity;
Stage #1: (2-butyl-5-chloro-3-{2'-[2-(1-methyl-1-phenyl-ethyl)-2H-tetrazol-5-yl]-biphenyl-4-ylmethyl}-3H-imidazol-4-yl)-methanol With hydrogenchloride In dichloromethane; water at 0 - 10℃; for 2h;
Stage #2: With sodium acetate In dichloromethane; water Product distribution / selectivity;
2-(2-methoxyphenyl)-4,4-dimethyl-2-oxazoline
57598-33-1

2-(2-methoxyphenyl)-4,4-dimethyl-2-oxazoline

lorsartan
114798-26-4

lorsartan

Conditions
ConditionsYield
Multi-step reaction with 6 steps
1: tetrahydrofuran / 2 h / 20 °C
2: 96 percent / pyridine, phosphorus oxychloride / 3 h / 100 °C
3: N-bromosuccinimide, dibenzoyl peroxide / CCl4 / 3 h / Heating
4: 1.) sodium methoxide / 1.) DMF, 25 deg C, 0.25 h, 2.) DMF, 40 deg C, 4 h
6: 89 percent / 10percent HCl / tetrahydrofuran / 4 h / 25 °C
View Scheme
Multi-step reaction with 7 steps
1: tetrahydrofuran / 2 h / 20 °C
2: 96 percent / pyridine, phosphorus oxychloride / 3 h / 100 °C
3: 1.) tributyltin chloride, sodium azide, 2.) 10 N aq. sodium hydroxide / 1.) toluene, reflux, 70 h, 20 deg C, 3 h
4: 92 percent / N-bromosuccinimide, dibenzoyl peroxide / CCl4 / 3 h / Heating
5: 49 percent / potassium carbonate / dimethylformamide / 24 h / 25 °C
6: sodium borohydride / CH2Cl2 / 24 h / 25 °C
7: 89 percent / 10percent HCl / tetrahydrofuran / 4 h / 25 °C
View Scheme
2-Cyano-4'-methylbiphenyl
114772-53-1

2-Cyano-4'-methylbiphenyl

lorsartan
114798-26-4

lorsartan

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1: N-bromosuccinimide, dibenzoyl peroxide / CCl4 / 3 h / Heating
2: 1.) sodium methoxide / 1.) DMF, 25 deg C, 0.25 h, 2.) DMF, 40 deg C, 4 h
4: 89 percent / 10percent HCl / tetrahydrofuran / 4 h / 25 °C
View Scheme
Multi-step reaction with 5 steps
1: 1.) tributyltin chloride, sodium azide, 2.) 10 N aq. sodium hydroxide / 1.) toluene, reflux, 70 h, 20 deg C, 3 h
2: 92 percent / N-bromosuccinimide, dibenzoyl peroxide / CCl4 / 3 h / Heating
3: 49 percent / potassium carbonate / dimethylformamide / 24 h / 25 °C
4: sodium borohydride / CH2Cl2 / 24 h / 25 °C
5: 89 percent / 10percent HCl / tetrahydrofuran / 4 h / 25 °C
View Scheme
Multi-step reaction with 4 steps
1: N-Bromosuccinimide; 2,2'-azobis(isobutyronitrile) / tetrachloromethane / 3 h / 80 °C / Green chemistry
2: potassium carbonate / N,N-dimethyl-formamide / 6 h / 40 °C / Green chemistry
3: sodium tetrahydroborate / methanol / 1.17 h / 20 - 40 °C / Green chemistry
4: sodium azide; zinc trifluoromethanesulfonate / water / 6 h / 100 °C / Green chemistry
View Scheme
Multi-step reaction with 3 steps
1: N-Bromosuccinimide / tetrachloromethane
2: sodium methylate / N-methyl-acetamide; hexane; ethyl acetate; N,N-dimethyl-formamide
3: ammonium chloride / ethanol; water; ethyl acetate; N,N-dimethyl-formamide; acetonitrile
View Scheme
2-n-butyl-4-chloro-5-hydroxymethylimidazole
79047-41-9

2-n-butyl-4-chloro-5-hydroxymethylimidazole

lorsartan
114798-26-4

lorsartan

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1: 77 percent / 1.0 N aq. ceric ammonium nitrate / acetic acid / 3 h / 25 °C
2: 49 percent / potassium carbonate / dimethylformamide / 24 h / 25 °C
3: sodium borohydride / CH2Cl2 / 24 h / 25 °C
4: 89 percent / 10percent HCl / tetrahydrofuran / 4 h / 25 °C
View Scheme
Multi-step reaction with 3 steps
1: NH4Ca(NO3)3; sodium hydroxide / acetic acid
2: sodium hydroxide; sodium tetrahydroborate / water; toluene
3: hydrogenchloride; sodium hydroxide; acetic acid / methanol; water; ethyl acetate; toluene
View Scheme
2-n-butyl-4-chloro-1H-imidazol-5-carboxaldehyde
83857-96-9

2-n-butyl-4-chloro-1H-imidazol-5-carboxaldehyde

lorsartan
114798-26-4

lorsartan

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: 49 percent / potassium carbonate / dimethylformamide / 24 h / 25 °C
2: sodium borohydride / CH2Cl2 / 24 h / 25 °C
3: 89 percent / 10percent HCl / tetrahydrofuran / 4 h / 25 °C
View Scheme
Multi-step reaction with 3 steps
1: potassium carbonate / acetonitrile / 20 h / 25 - 85 °C / Inert atmosphere
2: sodium tetrahydroborate / methanol; toluene / 0.5 h / 25 °C / Inert atmosphere
3: ammonium formate; 5% palladium on barium sulphate / isopropyl alcohol; water / 8 h / 25 - 60 °C
View Scheme
Multi-step reaction with 3 steps
1: potassium carbonate / N,N-dimethyl-formamide / 6 h / 40 °C / Green chemistry
2: sodium tetrahydroborate / methanol / 1.17 h / 20 - 40 °C / Green chemistry
3: sodium azide; zinc trifluoromethanesulfonate / water / 6 h / 100 °C / Green chemistry
View Scheme
Multi-step reaction with 3 steps
1.1: potassium carbonate / N,N-dimethyl acetamide / 5 h / 20 °C
2.1: sodium tetrahydroborate / methanol; N,N-dimethyl acetamide / 1 h / 5 - 20 °C
3.1: sodium azide; triethylamine hydrochloride / N,N-dimethyl acetamide / 16 h / 120 °C
3.2: 80 °C / pH 4.0
View Scheme
Multi-step reaction with 3 steps
1: sodium carbonate; tetraethylammonium bromide / toluene / 90 - 95 °C
2: sodium tetrahydroborate; sodium hydroxide / water / 20 - 85 °C
3: sodium azide; triethylamine hydrochloride / toluene / 90 - 95 °C
View Scheme
4'-(bromomethyl)-1,1'-biphenyl-2-carbonitrile
114772-54-2

4'-(bromomethyl)-1,1'-biphenyl-2-carbonitrile

lorsartan
114798-26-4

lorsartan

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: 1.) sodium methoxide / 1.) DMF, 25 deg C, 0.25 h, 2.) DMF, 40 deg C, 4 h
3: 89 percent / 10percent HCl / tetrahydrofuran / 4 h / 25 °C
View Scheme
Multi-step reaction with 3 steps
1: potassium carbonate / N,N-dimethyl-formamide / 6 h / 40 °C / Green chemistry
2: sodium tetrahydroborate / methanol / 1.17 h / 20 - 40 °C / Green chemistry
3: sodium azide; zinc trifluoromethanesulfonate / water / 6 h / 100 °C / Green chemistry
View Scheme
Multi-step reaction with 2 steps
1: sodium methylate / N-methyl-acetamide; hexane; ethyl acetate; N,N-dimethyl-formamide
2: ammonium chloride / ethanol; water; ethyl acetate; N,N-dimethyl-formamide; acetonitrile
View Scheme
Multi-step reaction with 3 steps
1.1: potassium carbonate / N,N-dimethyl acetamide / 5 h / 20 °C
2.1: sodium tetrahydroborate / methanol; N,N-dimethyl acetamide / 1 h / 5 - 20 °C
3.1: sodium azide; triethylamine hydrochloride / N,N-dimethyl acetamide / 16 h / 120 °C
3.2: 80 °C / pH 4.0
View Scheme
Multi-step reaction with 3 steps
1: sodium carbonate; tetraethylammonium bromide / toluene / 90 - 95 °C
2: sodium tetrahydroborate; sodium hydroxide / water / 20 - 85 °C
3: sodium azide; triethylamine hydrochloride / toluene / 90 - 95 °C
View Scheme
N-(2-hydroxy-1,1-dimethyl)-2-methoxybenzamide
74201-13-1

N-(2-hydroxy-1,1-dimethyl)-2-methoxybenzamide

lorsartan
114798-26-4

lorsartan

Conditions
ConditionsYield
Multi-step reaction with 7 steps
1: thionyl chloride / 1 h / 25 °C
2: tetrahydrofuran / 2 h / 20 °C
3: 96 percent / pyridine, phosphorus oxychloride / 3 h / 100 °C
4: N-bromosuccinimide, dibenzoyl peroxide / CCl4 / 3 h / Heating
5: 1.) sodium methoxide / 1.) DMF, 25 deg C, 0.25 h, 2.) DMF, 40 deg C, 4 h
7: 89 percent / 10percent HCl / tetrahydrofuran / 4 h / 25 °C
View Scheme
Multi-step reaction with 8 steps
1: thionyl chloride / 1 h / 25 °C
2: tetrahydrofuran / 2 h / 20 °C
3: 96 percent / pyridine, phosphorus oxychloride / 3 h / 100 °C
4: 1.) tributyltin chloride, sodium azide, 2.) 10 N aq. sodium hydroxide / 1.) toluene, reflux, 70 h, 20 deg C, 3 h
5: 92 percent / N-bromosuccinimide, dibenzoyl peroxide / CCl4 / 3 h / Heating
6: 49 percent / potassium carbonate / dimethylformamide / 24 h / 25 °C
7: sodium borohydride / CH2Cl2 / 24 h / 25 °C
8: 89 percent / 10percent HCl / tetrahydrofuran / 4 h / 25 °C
View Scheme
4,4-dimethyl-2-(4'-methyl-biphenyl-2-yl)-4,5-dihydrooxazole
84392-32-5

4,4-dimethyl-2-(4'-methyl-biphenyl-2-yl)-4,5-dihydrooxazole

lorsartan
114798-26-4

lorsartan

Conditions
ConditionsYield
Multi-step reaction with 5 steps
1: 96 percent / pyridine, phosphorus oxychloride / 3 h / 100 °C
2: N-bromosuccinimide, dibenzoyl peroxide / CCl4 / 3 h / Heating
3: 1.) sodium methoxide / 1.) DMF, 25 deg C, 0.25 h, 2.) DMF, 40 deg C, 4 h
5: 89 percent / 10percent HCl / tetrahydrofuran / 4 h / 25 °C
View Scheme
Multi-step reaction with 6 steps
1: 96 percent / pyridine, phosphorus oxychloride / 3 h / 100 °C
2: 1.) tributyltin chloride, sodium azide, 2.) 10 N aq. sodium hydroxide / 1.) toluene, reflux, 70 h, 20 deg C, 3 h
3: 92 percent / N-bromosuccinimide, dibenzoyl peroxide / CCl4 / 3 h / Heating
4: 49 percent / potassium carbonate / dimethylformamide / 24 h / 25 °C
5: sodium borohydride / CH2Cl2 / 24 h / 25 °C
6: 89 percent / 10percent HCl / tetrahydrofuran / 4 h / 25 °C
View Scheme
N-(trityl)-5-[4΄-(methyl)biphenyl-2-yl]-2H-tetrazole
133909-97-4

N-(trityl)-5-[4΄-(methyl)biphenyl-2-yl]-2H-tetrazole

lorsartan
114798-26-4

lorsartan

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1: 92 percent / N-bromosuccinimide, dibenzoyl peroxide / CCl4 / 3 h / Heating
2: 49 percent / potassium carbonate / dimethylformamide / 24 h / 25 °C
3: sodium borohydride / CH2Cl2 / 24 h / 25 °C
4: 89 percent / 10percent HCl / tetrahydrofuran / 4 h / 25 °C
View Scheme
N-(triphenylmethyl)-5-<4'-(bromomethyl)biphenyl-2-yl>tetrazole
133051-88-4

N-(triphenylmethyl)-5-<4'-(bromomethyl)biphenyl-2-yl>tetrazole

lorsartan
114798-26-4

lorsartan

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: 49 percent / potassium carbonate / dimethylformamide / 24 h / 25 °C
2: sodium borohydride / CH2Cl2 / 24 h / 25 °C
3: 89 percent / 10percent HCl / tetrahydrofuran / 4 h / 25 °C
View Scheme
2-n-Butyl-4-chloro-1-[(2'-(2-triphenylmethyl-2H-tetrazol-5-yl)-1,1'-biphenyl-4-yl)methyl]-1H-imidazole-5-carboxaldehyde
133910-00-6

2-n-Butyl-4-chloro-1-[(2'-(2-triphenylmethyl-2H-tetrazol-5-yl)-1,1'-biphenyl-4-yl)methyl]-1H-imidazole-5-carboxaldehyde

lorsartan
114798-26-4

lorsartan

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: sodium borohydride / CH2Cl2 / 24 h / 25 °C
2: 89 percent / 10percent HCl / tetrahydrofuran / 4 h / 25 °C
View Scheme
2-Methoxybenzoic acid
579-75-9

2-Methoxybenzoic acid

lorsartan
114798-26-4

lorsartan

Conditions
ConditionsYield
Multi-step reaction with 9 steps
1: 95 percent / thionyl chloride / 18 h / 20 °C
2: CH2Cl2 / 2 h / 20 °C
3: thionyl chloride / 1 h / 25 °C
4: tetrahydrofuran / 2 h / 20 °C
5: 96 percent / pyridine, phosphorus oxychloride / 3 h / 100 °C
6: N-bromosuccinimide, dibenzoyl peroxide / CCl4 / 3 h / Heating
7: 1.) sodium methoxide / 1.) DMF, 25 deg C, 0.25 h, 2.) DMF, 40 deg C, 4 h
9: 89 percent / 10percent HCl / tetrahydrofuran / 4 h / 25 °C
View Scheme
Multi-step reaction with 10 steps
1: 95 percent / thionyl chloride / 18 h / 20 °C
2: CH2Cl2 / 2 h / 20 °C
3: thionyl chloride / 1 h / 25 °C
4: tetrahydrofuran / 2 h / 20 °C
5: 96 percent / pyridine, phosphorus oxychloride / 3 h / 100 °C
6: 1.) tributyltin chloride, sodium azide, 2.) 10 N aq. sodium hydroxide / 1.) toluene, reflux, 70 h, 20 deg C, 3 h
7: 92 percent / N-bromosuccinimide, dibenzoyl peroxide / CCl4 / 3 h / Heating
8: 49 percent / potassium carbonate / dimethylformamide / 24 h / 25 °C
9: sodium borohydride / CH2Cl2 / 24 h / 25 °C
10: 89 percent / 10percent HCl / tetrahydrofuran / 4 h / 25 °C
View Scheme
2-Methoxybenzoyl chloride
21615-34-9

2-Methoxybenzoyl chloride

lorsartan
114798-26-4

lorsartan

Conditions
ConditionsYield
Multi-step reaction with 8 steps
1: CH2Cl2 / 2 h / 20 °C
2: thionyl chloride / 1 h / 25 °C
3: tetrahydrofuran / 2 h / 20 °C
4: 96 percent / pyridine, phosphorus oxychloride / 3 h / 100 °C
5: N-bromosuccinimide, dibenzoyl peroxide / CCl4 / 3 h / Heating
6: 1.) sodium methoxide / 1.) DMF, 25 deg C, 0.25 h, 2.) DMF, 40 deg C, 4 h
8: 89 percent / 10percent HCl / tetrahydrofuran / 4 h / 25 °C
View Scheme
Multi-step reaction with 9 steps
1: CH2Cl2 / 2 h / 20 °C
2: thionyl chloride / 1 h / 25 °C
3: tetrahydrofuran / 2 h / 20 °C
4: 96 percent / pyridine, phosphorus oxychloride / 3 h / 100 °C
5: 1.) tributyltin chloride, sodium azide, 2.) 10 N aq. sodium hydroxide / 1.) toluene, reflux, 70 h, 20 deg C, 3 h
6: 92 percent / N-bromosuccinimide, dibenzoyl peroxide / CCl4 / 3 h / Heating
7: 49 percent / potassium carbonate / dimethylformamide / 24 h / 25 °C
8: sodium borohydride / CH2Cl2 / 24 h / 25 °C
9: 89 percent / 10percent HCl / tetrahydrofuran / 4 h / 25 °C
View Scheme
2-n-butyl-4-chloro-5-hydroxymethyl-1-[[2'-(1H-tetrazole-5-yl)[1,1'-biphenyl]-4-yl]]-1H-imidazole magnesium salt

2-n-butyl-4-chloro-5-hydroxymethyl-1-[[2'-(1H-tetrazole-5-yl)[1,1'-biphenyl]-4-yl]]-1H-imidazole magnesium salt

lorsartan
114798-26-4

lorsartan

Conditions
ConditionsYield
With sulfuric acid In water; ethyl acetate at 10 - 25℃; for 1h; pH=3.6 - 3.8; Purification / work up;
2-n-butyl-4-chloro-5-hydroxymethyl-1-[[2'-(1H-tetrazole-5-yl)[1,1'-biphenyl]-4-yl]]-1H-imidazole calcium salt

2-n-butyl-4-chloro-5-hydroxymethyl-1-[[2'-(1H-tetrazole-5-yl)[1,1'-biphenyl]-4-yl]]-1H-imidazole calcium salt

lorsartan
114798-26-4

lorsartan

Conditions
ConditionsYield
With sulfuric acid In water; ethyl acetate at 10 - 25℃; for 1h; pH=3.6 - 3.8; Purification / work up;
lorsartan
114798-26-4

lorsartan

chloroacetic acid
79-11-8

chloroacetic acid

chloroacetyl losartan

chloroacetyl losartan

Conditions
ConditionsYield
With dmap; diisopropyl-carbodiimide In tetrahydrofuran at 0 - 20℃;100%
trityl chloride
76-83-5

trityl chloride

lorsartan
114798-26-4

lorsartan

2-Butyl-4-chloro-1-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol
124751-00-4

2-Butyl-4-chloro-1-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol

Conditions
ConditionsYield
With triethylamine In dichloromethane at 20℃; for 2h; Inert atmosphere;98.5%
With triethylamine In N,N-dimethyl-formamide at 0 - 20℃;96%
With triethylamine In N,N-dimethyl-formamide at 20℃;
lorsartan
114798-26-4

lorsartan

cozaar
124750-99-8

cozaar

Conditions
ConditionsYield
With potassium tert-butylate In isopropyl alcohol at 10 - 25℃; Product distribution / selectivity;94%
Stage #1: lorsartan With potassium hydroxide In isopropyl alcohol
Stage #2: In cyclohexane at 20 - 50℃; for 3h;
93.7%
With potassium hydroxide In water; acetonitrile for 0.25 - 0.333333h; Product distribution / selectivity;92%
lorsartan
114798-26-4

lorsartan

2-n-Butyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5-carboxaldehyde
114798-36-6

2-n-Butyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5-carboxaldehyde

Conditions
ConditionsYield
With dipyridinium dichromate In N,N-dimethyl-formamide at 20 - 50℃; for 6h; Alkaline conditions;94%
With 1-hydroxy-3H-benz[d][1,2]iodoxole-1,3-dione In dimethyl sulfoxide at 20℃; for 6h;53%
With ruthenium trichloride; potassium metaperiodate; diperiodatocuprate(III) dihydrate; potassium nitrate; potassium hydroxide In water at 25℃; for 2h; Kinetics; Temperature; Sealed tube; Inert atmosphere;
lorsartan
114798-26-4

lorsartan

losartan hydrochloride

losartan hydrochloride

Conditions
ConditionsYield
With hydrogenchloride In tetrahydrofuran93.7%
lorsartan
114798-26-4

lorsartan

losartan potassium
124750-99-8

losartan potassium

Conditions
ConditionsYield
With potassium hydroxide In methanol; isopropyl alcohol at 20℃; for 0.5h;90%
With potassium hydroxide In methanol for 4h; Heating / reflux;33%
With potassium hydroxide In methanol for 1h; pH=9; Reflux;
lorsartan
114798-26-4

lorsartan

2-n-butyl-4-chloro-5-hydroxymethyl-1-[[2'-(1H-tetrazole-5-yl)[1,1'-biphenyl]-4-yl]]-1H-imidazole sodium salt

2-n-butyl-4-chloro-5-hydroxymethyl-1-[[2'-(1H-tetrazole-5-yl)[1,1'-biphenyl]-4-yl]]-1H-imidazole sodium salt

Conditions
ConditionsYield
With sodium hydroxide In water; isopropyl alcohol at 38 - 40℃; for 0.5h; pH=10 - 12; Product distribution / selectivity;87%
With sodium t-butanolate In isopropyl alcohol Product distribution / selectivity;
With sodium hydroxide In water at 20℃; pH=9.62; Product distribution / selectivity;
L-N-Boc-Ala
15761-38-3

L-N-Boc-Ala

lorsartan
114798-26-4

lorsartan

(S)-(1-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-2-butyl-4-chloro-1H-imidazol-5-yl)methyl 2-(tert-butoxycarbonyl)aminopropanoate
1174760-85-0

(S)-(1-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-2-butyl-4-chloro-1H-imidazol-5-yl)methyl 2-(tert-butoxycarbonyl)aminopropanoate

Conditions
ConditionsYield
With 4-methyl-morpholine; benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In N,N-dimethyl-formamide at 0 - 20℃; for 24.5h;79%
lorsartan
114798-26-4

lorsartan

2-butyl-4-chloro-1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-1H-imidazole-5-carboxylic acid
124750-92-1

2-butyl-4-chloro-1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-1H-imidazole-5-carboxylic acid

Conditions
ConditionsYield
With pyridine; potassium permanganate; tetrabutyl-ammonium chloride In water; acetone at 40 - 50℃; for 1h; Product distribution / selectivity;78%
With sodium periodate; ruthenium(III) trichloride hydrate; potassium hydroxide In water at 0℃;
Stage #1: lorsartan With sodium periodate; ruthenium (III) chloride monohydrate; potassium hydroxide In water at 0℃;
Stage #2: In water; isopropyl alcohol at 25℃; for 2.5h;
Stage #3: With phosphoric acid In water; isopropyl alcohol at 30℃; for 0.5h;
With cytochrome P450 2C9 Enzymatic reaction;
With cytochrome b5; NADPH In aq. phosphate buffer at 37℃; for 0.75h; Kinetics; Reagent/catalyst; Enzymatic reaction;
lorsartan
114798-26-4

lorsartan

2-n-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol hydrobromide

2-n-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol hydrobromide

Conditions
ConditionsYield
With hydrogen bromide In tetrahydrofuran78%
lorsartan
114798-26-4

lorsartan

3‐[(nitrooxy)methyl]benzoic acid
646511-09-3

3‐[(nitrooxy)methyl]benzoic acid

3-nitrooxymethyl-benzoic acid 2-butyl-5-chloro-3-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-imidazol-4-ylmethyl ester

3-nitrooxymethyl-benzoic acid 2-butyl-5-chloro-3-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-imidazol-4-ylmethyl ester

Conditions
ConditionsYield
With dmap; dicyclohexyl-carbodiimide In tetrahydrofuran at 20℃; for 2h;72%
toluene-4-sulfonic acid
104-15-4

toluene-4-sulfonic acid

lorsartan
114798-26-4

lorsartan

2-n-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol p-toluenesulfonate

2-n-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol p-toluenesulfonate

Conditions
ConditionsYield
In tetrahydrofuran; chlorobenzene71.5%
pentafluorophenol 4-nitroxybutyrate
838878-70-9

pentafluorophenol 4-nitroxybutyrate

lorsartan
114798-26-4

lorsartan

2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-5-[(3-nitrooxypropyl)carbonyloxy]methyl-1H-imidazole
838876-22-5

2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-5-[(3-nitrooxypropyl)carbonyloxy]methyl-1H-imidazole

Conditions
ConditionsYield
With dmap; triethylamine In N,N-dimethyl-formamide at 0 - 20℃; for 4h;53%

114798-26-4Relevant articles and documents

Novel and efficient debenzylation of N-benzyltetrazole derivatives with the rosenmund catalyst

Seki, Masahiko

, p. 3249 - 3255 (2014)

The Rosenmund catalyst (Pd/BaSO4) was found to efficiently catalyze debenzylation of N-benzyltetrazole derivatives with ammonium formate by catalytic transfer hydrogenation under mild conditions. The protocol has been applied to functionalized substrates to provide various angiotensin II receptor blockers in excellent yields.

Unusual detritylation of tritylated tetrazole in Sartan molecules

Srimurugan, Sankareswaran,Suresh, Paulsamy,Babu, Balaji,Hiriyanna, Salmara Ganeshbhat,Pati, Hari Narayan

, p. 383 - 384 (2008)

Tritylated tetrazole of 2a underwent unusual detritylation under basic reaction condition during the synthesis of methyl ether of olmesartan medoxomil 1. The unusual detritylation was found to be a common feature in the case of all tetrazole containing Sartan molecules (3-7).

Method for preparing high-purity losartan

-

Paragraph 0020-0034, (2020/10/19)

The invention relates to a method for preparing high-purity losartan. The method comprises steps as follows: (1), a losartan crude product is added to an organic solvent or a mixed solvent of an organic solvent and water, and the mixture is heated to reach 20-80 DEG C and stirred; (2), the system is cooled directly or cooled after water is added or cooled to 0-5 DEG C after a part of solvent is evaporated, a material is precipitated, filtered and dried, and losartan is obtained, wherein the organic solvent used in the step (1) is any one of tetrahydrofuran, butanone, acetone and methyl alcohol or is a mixed solvent of any one of the four solvents and water. The losartan obtained with the method has high purity, any individual impurity can be reduced to 0.2% or even under 0.1%, the purity of the losartan can reach 99.5%, the cost of the method is lower, the refining yield is high, and the method is very simple in operation, environment-friendly and suitable for industrial production.

A trityl protecting group by removing method of preparing losartan medicine

-

Paragraph 0032-0039; 0047-0051, (2018/07/30)

The invention discloses a method for preparation of a Sartan drug by removal of a triphenylmethyl protective group. The method includes: under the catalysis of an insoluble weak acid, subjecting a Sartan prodrug and methanol to deprotection reaction, and after complete reaction, conducting aftertreatment to obtain the Sartan drug. The method has the characteristics of low cost, few side product, high quality product, and simple aftertreatment. At the same time, montmorillonite can be taken as insoluble weak acid, and the cost is low, thus being convenient for industrial production.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 114798-26-4